Sarepta Therapeutics, Inc. SRPT

That death cost this stock a 5 year FDA approval setback. At least. I hope you all got the info quick and was able to save a little before the big dip. Man that sucks luckily I stayed away and did not position.

$SRPT one morning I will wake up and this will be up over 1000%. One morning.

Kill ya self, Karen ????? $SRPT

????? kill ya self, Karen...

$SRPT totally manipulated. Japan approval is a slam dunk

$SRPT

Elevidys Approval: The FDA’s approval of Sarepta’s gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) has significantly bolstered the company’s market position. This therapy, priced at $3.2 million per patient, is projected to generate peak annual revenues of $3.3 billion by 2027, up from $1.1 billion in 2023.

Partnerships: In November 2024, Sarepta entered into a substantial licensing agreement with Arrowhead Pharmaceuticals, valued at over $11 billion. This deal provides Sarepta access to multiple clinical and preclinical RNAi programs, diversifying its pipeline beyond gene therapy.

Potential Acquirers
• Pfizer: 
• Other Pharma Giants: Companies like Roche, which already holds global rights to Elevidys, might consider acquiring Sarepta to consolidate their position in the neuromuscular disease market .

$SRPT pulled down for all stock BO

$SRPT buyout looks better now

$SRPT head fake. Recession proof company

$SRPT def not for the weak